Literature DB >> 2783572

The Aspergillus toxin restriction is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells.

F P Conde1, R Orlandi, S Canevari, D Mezzanzanica, M Ripamonti, S M Muñoz, P Jorge, M I Colnaghi.   

Abstract

The protein toxin restriction, isolated from the mould Aspergillus restrictus, inactivates protein synthesis in eukaryotic cells by blocking the ribosome elongation cycle. This protein acts as a specific nuclease that cuts off a small fragment from the 28-S rRNA. Biochemical and biological characterization of this toxin indicated that it is a non-glycosylated polypeptide of Mr 16836, exhibiting in cell-free systems a protein synthesis inhibition capacity similar to that of the ricin A chain. This polypeptide seemed unable to penetrate most of the cancer cell lines tested, as measured by its low in vitro cytotoxicity. In addition in vivo studies in BALB/c mice demonstrated that restriction toxicity was very low and that in rabbits, after intravenous injection 15% of the toxin was still present in the blood stream 24 h later. After derivatization with N-succinimidyl 3-(2-pyridyldithio)propionate and reduction by dithiothreitol, the restrictocin maintained its protein synthesis inhibitory activity, as assayed in a cell-free system. This derivatized toxin was then coupled to monoclonal antibodies (MBr1, MLuC1, MLuC2, MOv17, MOv18, MOv19) which exhibited a restricted spectrum of reactivity against human carcinomas. The biochemical and biological characterization of the immunoconjugates indicated that (a) when restrictocin was coupled to monoclonal antibodies with an average molar ratio of about 2, the immunoconjugates maintained the binding activity of the antibody and protein synthesis inhibition activity of the toxin; (b) four immunoconjugates were tested for cytotoxicity and three of them obtained with the MBr1, MLuC1 and MOv17 monoclonal antibodies exhibited a good level of cytotoxicity for relevant target cells and low or no toxicity for the irrelevant cell lines. The MLuC2 monoclonal antibody which gave rise to a completely ineffective immunoconjugate, induced internalization of less than one tenth of the antigenic sites whereas the MBr1, MLuC1 and MOv17 monoclonal antibodies exhibited about one third of the antigenic sites interanalized. From these data it is concluded that, providing an appropriate target antigen and coupling procedure are selected, restrictocin can be considered a suitable toxin for immunoconjugate generation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783572     DOI: 10.1111/j.1432-1033.1989.tb14511.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Isolation and nucleotide sequence of the Aspergillus restrictus gene coding for the ribonucleolytic toxin restrictocin and its expression in Aspergillus nidulans: the leader sequence protects producing strains from suicide.

Authors:  B Lamy; J Davies
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

2.  Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.

Authors:  A Goyal; J K Batra
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

Review 3.  Microbial ribonucleases (RNases): production and application potential.

Authors:  E Esin Hameş; Tuğçe Demir
Journal:  World J Microbiol Biotechnol       Date:  2015-10-03       Impact factor: 3.312

4.  Construction, expression and characterization of chimaeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action.

Authors:  D Rathore; J K Batra
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

5.  Identification and evaluation of a major cytotoxin of A. fumigatus.

Authors:  T Madan; N Arora; P U Sarma
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

6.  Transformation of Aspergillus giganteus to hygromycin B resistance.

Authors:  S Wnendt; M Jacobs; U Stahl
Journal:  Curr Genet       Date:  1990-01       Impact factor: 3.886

7.  A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.

Authors:  P Casalini; M Caldera; S Canevari; S Ménard; D Mezzanzanica; E Tosi; M Gadina; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 8.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.